Medexus Pharmaceuticals Inc T.MDP

Alternate Symbol(s): MEDXF

Healthcare

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its lead products are IXINITY (US), Rupall (Canada), Rasuvo (US) and Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.

TSX:MDP - Post by User

Medexus Pharmaceuticals Inc > Ebitda Sector Multiple

<< Previous

Bullboard Posts

Next >>

Post by nozzpackon Aug 04, 2023 1:06pm

184 Views

Post# 35573651

Ebitda Sector Multiple

Approximately 13 times for this sector..

https://firstpagesage.com/business/pharmaceutical-company-valuation-ebitda-multiples/

Trailing, MDP had $16.1 million US in Ebitda in 2022 which is about $21 million in CAD equivalent to a fair value of about $275 million CAD or about $13 per share.

MDP had Ebitda of $4,8 million US in Q4 of 2022 on $28 m in Revenur

Projecting forward for 2023, this would be about $24 million CAD or about $310 million market cap.

That would be about $15 per share assuming no growth in 2023.

As the revenue for Q1 of 2023 is already known to be in excess of $31 million US, $15 per share may be conservative .

So, another peer based valuation shows tremendous upside here,l